Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abasaglar

- PMLiVE

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Beyfortus showed an over 80% reduction in hospitalisations associated with the virus

- PMLiVE

Boehringer Ingelheim and 3T announce second cancer immunotherapy partnership

The collaboration brings the potential milestone payments of the agreements to $538.5m

- PMLiVE

Boehringer Ingelheim and Ribo announce liver disease partnership worth over $2bn

More than 440 million people worldwide are estimated to live with the inflammatory liver disease NASH

- PMLiVE

Sanofi and AI specialist Aqemia enter $140m drug discovery partnership

The deal is aimed at discovering small molecule drugs across several therapeutic areas

- PMLiVE

Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas

Approximately 18,740 new cases of CLL have been diagnosed in the US this year

- PMLiVE

Eli Lilly and PRISM BioLab enter drug discovery collaboration worth over $660m

The partnership is aimed at discovering oral inhibitors of a PPI target selected by Lilly

- PMLiVE

Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership

The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

About 300,000 people in the US have uncontrolled COPD and type 2 inflammation

- PMLiVE

Boehringer Ingelheim to acquire T3 Pharmaceuticals in deal worth over $500m

The acquisition marks a significant boost to Boehringer’s immuno-oncology portfolio

- PMLiVE

Eli Lilly to expand injectable manufacturing capacity with new $2.5bn facility in Germany

The site is expected to be operational in 2027 and will employ up to 1,000 highly skilled workers

- PMLiVE

Almirall granted EC approval for Ebglyss in moderate-to-severe atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

- PMLiVE

Eli Lilly’s tirzepatide injection approved by MHRA and FDA for weight loss in adults

The drug has been authorised for use alongside a reduced-calorie diet and physical activity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links